
Life Sciences · NYSE: WAT
Waters earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 8 Feb 2027
Latest: Q3 2026
Waters is integrating the BD Biosciences and Diagnostic Solutions businesses ahead of schedule, launching FACSDiscover A7 and buying MOBILion Systems to enter proteomics, while raising full-year guidance.
Waters's legacy analytical business grew 9% in constant currency, led by chemistry consumables and LC-MS instruments. Management cited instrument replacement, GLP-1s, PFAS and India generics as drivers. In the acquired businesses, reagents accelerated, China local manufacturing restored growth in Biosciences, and the new FACSDiscover A7 flow cytometer launched late in the quarter. Net price realization reached 120bps.
Quarters
KPI history
Data
| Q4 2024 | $872.7M |
| Q1 2025 | $661.7M |
| Q2 2025 | $771.3M |
| Q3 2025 | $799.9M |
| Q4 2025 | $932.4M |
| Q1 2026 | $1.3B |
| Q2 2026 | $1.6B |
| Q3 2026 | $1.8B |
Data
| Q4 2024 | $3.88 |
| Q1 2025 | $2.03 |
| Q2 2025 | $2.47 |
| Q3 2025 | $2.50 |
| Q4 2025 | $3.77 |
| Q1 2026 | -$0.87 |
| Q2 2026 | -$1.39 |
| Q3 2026 | $0.82 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | 33.5% |
| Q1 2025 | 22.9% |
| Q2 2025 | 24.4% |
| Q3 2025 | 24.0% |
| Q4 2025 | 29.0% |
| Q1 2026 | -3.7% |
| Q2 2026 | -5.2% |
| Q3 2026 | 7.2% |
Data
| Q1 2025 | $234.0M |
| Q2 2025 | $18.0M |
| Q3 2025 | $162.0M |
| Q4 2025 | $125.8M |
| Q1 2026 | -$42.0M |
| Q2 2026 | $153.0M |
| Q3 2026 | $54.0M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $872.7M | $661.7M | $771.3M | $799.9M | $932.4M | $1.3B | $1.6B | $1.8B |
| Operating income | $292.3M | $151.7M | $188.2M | $192.1M | $270.5M | -$47.0M | -$86.0M | $128.0M |
| Operating margin | 33.5% | 22.9% | 24.4% | 24.0% | 29.0% | -3.7% | -5.2% | 7.2% |
| Net income | $231.4Md | $121.4M | $147.1M | $148.9M | $225.6Md | -$72.0M | -$136.0M | $81.0M |
| Diluted EPS | $3.88 | $2.03 | $2.47 | $2.50 | $3.77 | -$0.87 | -$1.39 | $0.82 |
| Operating cash flow | $240.1Md | $260.0M | $41.0Md | $187.0Md | $164.6Md | -$3.0M | $201.0Md | $117.0Md |
| Capital expenditure | — | $26.0M | $23.0Md | $25.0Md | $38.7Md | $39.0M | $48.0Md | $63.0Md |
| Free cash flow | — | $234.0M | $18.0M | $162.0M | $125.8M | -$42.0M | $153.0M | $54.0M |
| R&D expense | $46.9M | $46.6M | $48.5M | $53.6M | $46.9M | $96.0M | $122.0M | $106.0M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 10 Nov 202610-Q for the period ended 3 Oct 2026SEC ↗
- 11 Aug 202610-Q for the period ended 4 Jul 2026SEC ↗
- 12 May 202610-Q for the period ended 4 Apr 2026SEC ↗
- 23 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 4 Nov 202510-Q for the period ended 27 Sep 2025SEC ↗
- 4 Aug 202510-Q for the period ended 28 Jun 2025SEC ↗
- 6 May 202510-Q for the period ended 29 Mar 2025SEC ↗
- 25 Feb 202510-K for the period ended 31 Dec 2024SEC ↗